Therapies for adrenal insufficiency

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 9, 2007, Pages 1283-1291

  Oki, Kenji ^a   Yamane, Kiminoti ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Addison's disease; Adrenal crisis; Adrenal insufficiency; Dehydroepiandrosterone; Glucocorticoid; Mineralocorticoid

Indexed keywords

ALDOSTERONE; BARBITURIC ACID DERIVATIVE; CARBENOXOLONE; CATECHOLAMINE; CORTISONE ACETATE; DEOXYCORTICOSTERONE; DEXAMETHASONE; FLUDROCORTISONE; GLUCOCORTICOID; HYDROCORTISONE; LIOTHYRONINE; METHYLPREDNISOLONE; MINERALOCORTICOID; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRASTERONE; PREDNISOLONE; PREDNISONE; RIFAMPICIN; SODIUM CHLORIDE;

ADRENAL CORTEX INSUFFICIENCY; ADRENAL INSUFFICIENCY; ANDROGEN THERAPY; BODY COMPOSITION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; CORTICOSTEROID THERAPY; CRITICAL ILLNESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG POTENTIATION; EMERGENCY TREATMENT; EVIDENCE BASED MEDICINE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPONATREMIA; HYPOVOLEMIA; LOW DRUG DOSE; MAINTENANCE THERAPY; OPTIMAL DRUG DOSE; REVIEW; SCALP PRURITUS; SEXUALITY; SWEAT GLAND DISEASE; WELLBEING; DRUG ADMINISTRATION; HORMONE SUBSTITUTION; TREATMENT OUTCOME;

ADRENAL INSUFFICIENCY; DEHYDROEPIANDROSTERONE; DRUG ADMINISTRATION SCHEDULE; FLUDROCORTISONE; HORMONE REPLACEMENT THERAPY; HUMANS; HYDROCORTISONE; TREATMENT OUTCOME;

EID: 34250855676     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.9.1283     Document Type: Review

References (68)

1. DORIN RI, QUALLS CR, CRAPO LM: Diagnosis of adrenal insufficiency. Ann. Intern. Med. (2003) 139:194-204.
2. TEN S, NEW M, MACLAREN N: Clinical review 130: Addison's disease 2001. J. Clin. Endocrinol. Metab. (2001) 86:2909-2922.
3. OKI K, MATSUURA W, KOIDE J et al.: Ampulla cardiomyopathy associated with adrenal insufficiency and hypothyroidism. Int. J. Cardiol. (2006) 108:391-392.
4. OKI K, NODA K, KONDO K, KOIDE J: Rhabdomyolysis associated with hyponatremia and adrenal insufficiency. Eur. J. Neurol. (2006) 13:e8-e9.
5. HELLMIG S, STUBER E, FOLSCH U, KOSMAHL M: Complications of an Addisonian crisis. Gut (2004) 53:1219-1234.
6. ADDISON T: On the constitutional and local effects of disease of the supla-renal capsules. Warren & Son. London (1855):1-42.
7. OELKERS W: Adrenal insufficiency. N. Engl. J. Med. (1996) 335:1206-1212.
8. FALORNI A, LAURETI S, DE BELLIS A et al.: Italian addison network study: update of diagnostic criteria for the etiological classification of primary adrenal insufficiency. J. Clin. Endocrinol. Metab. (2004) 89:1598-1604.
9. ALEVRITIS EM, SARUBBI FA, JORDAN RM, PEIRIS AN: Infectious causes of adrenal insufficiency. South Med. J. (2003) 96:888-890.
10. ARLT W, ALLOLIO B: Adrenal insufficiency. Lancet (2003) 361:1881-1893.
11. KERRIGAN JR, VELDHUIS JD, LEYO SA, IRANMANESH A, ROGOL AD: Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. J. Clin. Endocrinol. Metab. (1993) 76:1505-1510.
12. SLAG MF, AHMAD M, GANNON MC, NUTTALL FQ: Meal stimulation of cortisol secretion: a protein induced effect. Metabolism (1981) 30:1104-1108.
13. YOUNG EA, ABELSON J, LIGHTMAN SL: Cortisol pulsatility and its role in stress regulation and health. Front. Neuroendocrinol. (2004) 25:69-76.
14. KRASNER AS: Glucocorticoid-induced adrenal insufficiency. JAMA (1999) 282:671-676.
15. ESTEBAN NV, LOUGHLIN T, YERGEY AL et al.: Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J. Clin. Endocrinol. Metab. (1991) 72:39-45.
16. KERRIGAN JR, VELDHUIS JD, LEYO SA, IRANMANESH A, ROGOL AD: Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. J. Clin. Endocrinol. Metab. (1993) 76:1505-1510.
17. KRAAN GP, DULLAART RP, PRATT JJ, WOLTHERS BG, DRAYER NM, DE BRUIN R: The daily cortisol production reinvestigated in healthy men. The serum and urinary cortisol production rates are not significantly different. J. Clin. Endocrinol. Metab. (1998) 83:1247-1252.
18. BRANDON DD, ISABELLE LM, SAMUELS MH, KENDALL JW, LORIAUX DL: Cortisol production rate measurement by stable isotope dilution using gas chromatography-negative ion chemical ionization mass spectrometry. Steroids (1999) 64:372-378.
19. MAH PM, JENKINS RC, ROSTAMI-HODJEGAN A et al.: Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal sufficiency. Clin. Endocrinol. (Oxf) (2004) 61:367-375.
20. TANNIN GM, AGARWAL AK, MONDER C, NEW MI, WHITE PC: The human gene for 11 β-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. J. Biol. Chem. (1991) 266:16653-16658.
21. DIEDERICH S, QUINKLER M, BURKHARDT P, GROSSMANN C, BAHR V, OELKERS W: 11 β-hydroxysteroid-dehydrogenase isoforms: tissue distribution and implications for clinical medicine. Eur. J. Clin. Invest. (2000) 30(Suppl. 3):21-27.
22. WALKER BR, PHILLIPS DI, NOON JP et al.: Increased glucocorticoid activity in men with cardiovascular risk factors. Hypertension (1998) 31:891-895.
23. CROWN A, LIGHTMAN S: Why is the management of glucocorticoid deficiency still controversial: a review of the literature. Clin. Endocrinol. (Oxf) (2005) 63:483-492.
24. ZELISSEN PM, CROUGHS RJ, VAN RIJK PP, RAYMAKERS JA: Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann. Intern. Med. (1994) 120:207-210.
25. JEFFCOATE W: Assessment of corticosteroid replacement therapy in adults with adrenal insufficiency. Ann. Clin. Biochem. (1999) 36:151-157.
26. GROVES RW, TOMS GC, HOUGHTON BJ, MONSON JP: Corticosteroid replacement therapy: twice or thrice daily? J. R. Soc. Med. (1988) 81:514-516.
27. HOWLETT TA: An assessment of optimal hydrocortisone replacement therapy. Clin. Endocrinol. (Oxf) (1997) 46:263-268.
28. KEHLET H, BINDER C, BLICHERT-TOFT M: Glucocorticoid maintenance therapy following adrenalectomy: assessment of dosage and preparation. Clin. Endocrinol. (Oxf) (1976) 5:37-41.
29. FEEK CM, RATCLIFFE JG, SETH J, GRAY CE, TOFT AD, IRVINE WJ: Patterns of plasma cortisol and ACTH concentrations in patients with Addison's disease treated with conventional corticosteroid replacement. Clin. Endocrinol. (Oxf) (1981) 14:451-458.
30. LOVAS K, THORSEN TE, HUSEBYE ES: Saliva cortisol measurement: simple and reliable assessment of the glucocorticoid replacement therapy in Addison's disease. J. Endocrinol. Invest. (2006) 29:727-731.
31. WONG V, YAN T, DONALD A, MCLEAN M: Saliva and bloodspot cortisol: novel sampling methods to assess hydrocorcisone replacement therapy in hypoadrenal patients. Clin. Endocrinol. (Oxf) (2004) 61:131-137.
32. WILKINS EG, HNIZDO E, COPE A: Addisonian crisis induced by treatment with rifampicin. Tubercle. (1989) 70:69-73.
33. OGG MS, GRAY TJ, GIBSON GG: Development of an in vitro reporter gene assay to assess xenobiotic induction of the human CYP3A4 gene. Eur. J. Drug. Metab. Pharmacokinet. (1997) 22:311-313.
34. LIDDLE C, GOODWIN BJ, GEORGE J, TAPNER M, FARRELL GC: Separate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes. J. Clin. Endocrinol. Metab. (1998) 83:2411-2416.
35. MANTERO F, PALERMO M, PETRELLI MD, TEDDE R, STEWART PM, SHACKLETON CH: Apparent mineralocorticoid excess: type I and type II. Steroids (1996) 61:193-196.
36. WHITE PC: 11 β-hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess. Am. J. Med. Sci. (2001) 322:308-315.
37. OELKERS W, DIEDERICH S, BAHR V: Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone. J. Clin. Endocrinol. Metab. (1992) 75:259-264.
38. FLAD TM, CONWAY JD, CUNNINGHAM SK, MCKENNA TJ: The role of plasma renin activity in evaluating the adequacy of mineralocorticoid replacement in primary adrenal insufficiency. Clin. Endocrinol. (Oxf) (1996) 45:529-534.
39. BIGLIERI EG, KATER CE: Mineralocorticoids in congenital adrenal hyperplasia. J. Steroid. Biochem. Mol. Biol. (1991) 40:493-499.
40. LOPES LA, DUBUIS JM, VALLOTRON MB, SIZONENKO PC: Should we monitor more closely the dosage of 9 α-fluorohydrocortisone in salt-losing congenital adrenal hyperplasia? J. Pediatr. Endocrinol. Metab. (1998) 11:733-737.
41. ORENTREICH N, BRIND JL, RIZER RL, VOGELMAN JH: Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J. Clin. Endocrinol. Metab. (1984) 59:551-555.
42. BUTENANDT A, DANENBAUM H: Isolietung neuen, physiologisch unwirksamen Sterindervates aus Mannerharn, Seine Verknupfung mit Dehdroandrosterone und Androsteron. Z. Physiol. Chem. (1934) 229:192-195.
43. KALMIJN S, LAUNER LJ, STOLK RP et al.: A prospective study on cortisol, dehydroepiandrosterone sulfate, and cognitive function in the elderly. J. Clin. Endocrinol. Metab. (1998) 83:3487-3492.
44. FONDA SJ, BERTRAND R, O'DONNELL A, LONGCOPE C, MCKINLAY JB: Age, hormones, and cognitive functioning among middle-aged and elderly men: cross-sectional evidence from the Massachusetts Male Aging Study. J. Gerontol. A. Biol. Sci. Med. Sci. (2005) 60:385-390.
45. ROBERTS E, BELUGA L, FLOOD JF, SMITH GE: Effects of dehydroepiandrosterone and its sulfate on brain tissue in culture and on memory in mice. Brain. Res. (1987) 406:357-362.
46. BOLOGA L, SHARMA J, ROBERTS E: Dehydroepiandrosterone, and its sulfated derivative reduce neuronal death and enhance astrocytic differentiation in brain cell cultures. J. Neurosci. Res. (1987) 17:225-234.
47. ARLT W, JUSTL HG, CALLIES F et al.: Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. J. Clin. Endocrinol. Metab. (1998) 83:1928-1934.
48. KIMONIDES VG, SPILLANTINI MG, SOFRONIEW MV, FAWCETT JW, HERBERT J: Dehydroepiandrosterone antagonizes the neurotoxic effects of corticosterone and translocation of stress-activated protein kinase 3 in hippocampal primary cultures. Neuroscience (1999) 89:429-436.
49. NAIR KS, RIZZA RA, O'BRIEN P: Effects of dehydroepiandrosterone and atamestane supplementation on frailty in elderly men. J. Clin. Endrocrinol. Metab. (2006) 91:3988-3991.
50. CAMERON DR, BRAUNSTEIN GD: The use of dehydroepiandrosterone therapy in clinical practice. Treat. Endocrinol. (2005) 4:95-114.
51. LOVAS Y, LOGE JH, HUSEBYE ES: Subjective health status in Norwegian patients with Addison's disease. Clin. Endocrinol. (Oxf) (2002) 56:581-588.
52. ARLT W, CALLIES F, VAN VLIJMEN JC et al.: Dehydroepiandrosterone replacement in women with adrenal insufficiency. N. Engl. J. Med. (1999) 341:1013-1020.
53. HUNT PJ, GURNELL EM, HUPPERT FA et al.: Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. J. Clin. Endocrinol. Metab. (2000) 85:4650-4656.
54. JOHANNSSON G, BURMAN P, WIREN L et al.: Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. J. Clin. Endocrinol. Metab. (2002) 87:2046-2052.
55. LOVAS K, GEBRE-MEDHIN G, TROVIK TS et al.: Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial. J. Clin. Endocrinol. Metab. (2003) 88:1112-1118.
56. COLES AJ, THOMPSON S, COX AL, CURRAN S, GURNELL EM, CHATTERJEE VK: Dehydroepiandrosterone replacement in patients with Addison's disease has a bimodal effect on regulatory (CD4(+)CD25(hi) and CD4(+)FoxP3(+)) T cells. Eur. J. Immunol. (2005) 35:3694-3703.
57. CHRISTIANSEN JJ, GRAVROLT CH, FISKER S et al.: Very short term dehydroepiandrosterone treatment in female adrenal failure: impact on carbohydrate, lipid and protein metabolism. Eur. J. Endocrinol. (2005) 152:77-85.
58. DHATARIYA Y, BIGELOW ML, NAIR KS: Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes (2005) 54:765-769.
59. DRUCKER D, SHANDLING M: Variable adrenocortical function in acute medical illness. Crit. Care. Med. (1985) 13:477-479.
60. PARKER LN, LEVIN ER, LIFRAK ET: Evidence for adrenocortical adaptation to severe illness. J. Clin. Endocrinol. Metab. (1985) 60:947-952.
61. LAMBERTS SW, BRUINING HA, DE JONG FH: Corticosteroid therapy in severe illness. N. Engl. J. Med. (1997) 337:1285-1292.
62. JABBOUR SA: Steroids and the surgical patient. Med. Clin. North Am. (2001) 85:1311-1317.
63. SALEM M, TAINSH RE JR, BROMBERG J, LORIAUX DL, CHERNOW B: Perioperative glucocorticoid coverage. A reassessment 42 years after emergence of a problem. Ann. Surg. (1994) 219:416-425.
64. ZALOGA GP, MARIK P: Hypothalamic-pituitary-adrenal insufficiency. Crit. Care. Clin. (2001) 17:25-41.
65. CRONIN L, COOK DJ, CARLET J et al.: Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit. Care. Med. (1995) 23:1430-1439.
66. NIEBOER P, VAN DER WERF TS, BEENTJES JA, TULLEKEN JE, ZIJLSTRA JG, LIGTENBERG JJ: Catecholamine dependency in a polytrauma patient: relative adrenal insufficiency? Intensive Care. Med. (2000) 26:125-127.
67. COURSIN DB, WOOD KE: Corticosteroid supplementation for adrenal insufficiency. JAMA (2002) 287:236-240.
68. COOPER MS, STEWART PM: Corticosteroid insufficiency in acutely ill patients. N. Engl. J. Med. (2003) 348:727-734.